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Ursodeoxycholic acid (UDcA) treatment can reduce itch and lower endogenous serum bile acids in 
intrahepatic cholestasis of pregnancy (ICP). We sought to determine how it could influence the gut 
environment in icp to alter enterohepatic signalling. the gut microbiota and bile acid content were 
determined in faeces from 35 pregnant women (14 with uncomplicated pregnancies and 21 with ICP, 
17 receiving UDCA). Faecal bile salt hydrolase activity was measured using a precipitation assay. 
Serum fibroblast growth factor 19 (FGF19) and 7α-hydroxy-4-cholesten-3-one (C4) concentrations 
were measured following a standardised diet for 21 hours. Women with a high ratio of Bacteroidetes 
to Firmicutes were more likely to be treated with UDcA (fisher’s exact test p = 0.0178) than those with 
a lower ratio. Bile salt hydrolase activity was reduced in women with low Bacteroidetes:Firmicutes. 
Women taking UDcA had higher faecal lithocholic acid (p < 0.0001), with more unconjugated bile acids 
than women with untreated ICP or uncomplicated pregnancy. UDCA-treatment increased serum FGF19, 
and reduced C4 (reflecting lower bile acid synthesis). During ICP, UDCA treatment can be associated 
with enrichment of the gut microbiota with Bacteroidetes. these demonstrate high bile salt hydrolase 
activity, which deconjugates bile acids enabling secondary modification to FXR agonists, enhancing 
enterohepatic feedback via FGF19.
The serum and faecal bile acid composition is intimately related to biotransformation of bile acids by intestinal 
bacteria, and their subsequent enterohepatic circulation. Deconjugation of primary bile acids by bacterial bile 
salt hydrolase (BSH) enables unconjugated bile acids to be modified to secondary bile acids. Bile acids act as 
signalling molecules for many different end organs (e.g. liver, pancreas, adipose tissue, inflammatory cells), with 
individual bile acid species of differing ligand potency for different receptors (e.g. farnesoid X receptor (FXR), 
Takeda G-protein-coupled receptor 5 (TGR5))1–3.
Intrahepatic cholestasis of pregnancy (ICP) is predominantly a liver disorder specific to pregnancy, defined 
by pruritus and elevated serum bile acids beyond the normal asymptomatic hypercholanaemia of pregnancy. 
Fetal adverse outcomes are related to the extent of elevation of serum concentrations of total bile acids4,5. Women 
with ICP have increased rates of impaired glucose tolerance, gestational diabetes mellitus, and dyslipidaemia6,7. 
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The drug ursodeoxycholic acid (UDCA) improves itch severity and alters the composition of the serum bile acid 
pool in ICP8,9. Previous studies have suggested that UDCA may be of additional benefit for women with ICP, for 
example by normalising the ICP-related fall in glucagon-like peptide 1 (GLP1) release following a meal6. Indeed, 
murine studies have demonstrated that UDCA treatment can lower blood glucose concentrations in mice fed a 
high-fat diet10.
A number of studies have established that the gut microbiota changes during pregnancy, and this can be 
associated with the gestational metabolic alterations observed in late pregnancy11–13. We hypothesised that the 
metabolic improvements associated with UDCA treatment of ICP are contributed to by the beneficial effects of 
an altered intestinal microbiota, providing enhanced enterohepatic feedback. Human studies of the intestinal 
microbiota are complicated by inter-individual differences in diet, environment and genetics. Furthermore, the 
composition of the intestinal content must be inferred from faecal samples, particularly during pregnancy, when 
endoscopy for research is relatively contra-indicated. We therefore used a murine model to further interrogate 
the effects observed in humans. Cholic acid (CA) dietary supplementation has previously been demonstrated to 
result in serum bile acid concentrations comparable to those observed in ICP14; we used this model in combina-
tion with UDCA dietary supplementation to assess effects on the caecal gut microbiota to support our human 
results.
Results
Human intestinal microbiota in normal and UDcA-treated cholestatic pregnancies. To deter-
mine the effect of UDCA treatment on the composition of the gut microbiota, metataxonomics was performed 
on faecal samples from fourteen women with normal pregnancies, four women with untreated ICP, and seventeen 
women with UDCA-treated ICP (Supplementary Table S1).
There was an overall increase in the relative abundance of Bacteroidetes compared with Firmicutes, the two 
most populous phyla in the colonic microbiota, in the women treated with UDCA (Fig. 1a, Supplementary 
Fig. S1). Unsupervised hierarchical clustering revealed that the faecal samples clustered into three groups accord-
ing to the ratio of Bacteroidetes to Firmicutes (Fig. 1b,c), and this clustering continued to order level, revealing 
the same groups with the ratio of Bacteroidales to Clostridiales (Supplementary Fig. S2). Women with a high 
Bacteroidetes to Firmicutes ratio were more likely to be treated with UDCA than women with lower ratios 
(p = 0.0178, Fisher’s exact test compared with both low and parity of Bacteroidetes:Firmicutes, p = 0.0412, 
Freeman Halton extension of Fisher’s exact test compared between each cluster). For the women treated with 
UDCA, those with a high ratio of Bacteroidetes to Firmicutes received a greater total dose of UDCA prior to the 
sample being collected (p = 0.004) than those with parity or a low ratio; there was no other difference between 
the groups (Table 1).
We have previously demonstrated in mice that caecal Bacteroidetes-encoded BSH capacity increased in preg-
nancy and in a model of CA dietary supplementation13. An assay of BSH activity was therefore performed, which 
demonstrated that faecal samples with lower Bacteroidetes than Firmicutes indeed did have reduced enzymatic 
activity (p = 0.0379) (Fig. 1d).
Faecal bile acid profile in women with cholestatic and normal pregnancies, demonstrating the 
effect of UDCA treatment. Faecal samples were subsequently assayed to determine bile acid composition. 
In UDCA-treated women with ICP, UDCA and its metabolite, lithocholic acid (LCA), predominated (Fig. 2a). 
This group also had significantly higher proportions of unconjugated bile acids than those with normal preg-
nancies (Fig. 2b). Faecal samples with a higher ratio of Bacteroidetes:Firmicutes had significantly more bile acids 
per gram than those with low or parity of Bacteroidetes:Firmicutes (Fig. 2c); this was true for both unconjugated 
and conjugated bile acids. In turn, high BSH activity was associated with reduced taurine-conjugated bile acids 
(Fig. 2d).
We have previously demonstrated the effect of UDCA treatment on individual serum bile acids15, with UDCA 
comprising approximately 60% (42.8–69.0%, median (IQR)) of the bile acid pool in treated, and 0.3% (0.0–0.9%) 
in untreated women. To determine the relative effect on classical and alternative pathways of bile acid synthe-
sis, we used this dataset to compare the ratio of CA to chenodeoxycholic acid (CDCA) following treatment 
(Supplementary Fig. S3). The proportion of CA reduced compared to CDCA for women who had taken at least 
14 g UDCA (p = 0.04), with 83% (15/18) with lower CA:CDCA than prior to treatment (Supplementary Table S2).
Since bile acids have different potencies with respect to FXR activation, we assessed the impact of ICP on intes-
tinal FXR signalling by measuring the serum concentration of FGF19 in a separate cohort of women with ICP 
and normal pregnancies given a standardised diet over 24 hours. Treatment with UDCA significantly increased 
peak circulating FGF19 (Fig. 2e) with a corresponding reduction in serum 7α-hydroxy-4-cholesten-3-one (C4) 
concentration. Similarly, the effects of the secondary metabolites of UDCA on intestinal release of GLP1 were 
determined using primary murine colonic cultures. Incubation with LCA and deoxycholic acid (DCA) resulted 
in release of GLP1 from intestinal crypts that was not seen in control incubations (Fig. 2f).
Murine model of dietary hypercholanaemia, to determine the effects of UDCA treatment. To 
support these findings, we performed metataxonomics on the caecal content of mice fed a normal chow control 
diet, and diets supplemented with 0.5% CA, 0.5% UDCA and 0.5% CA plus 0.5% UDCA immediately prior to and 
during pregnancy. Dietary supplementation with bile acids significantly altered the composition of the gut micro-
biota, with mice clustering according to their diet groups (Fig. 3a,b, Supplementary Table S3, Supplementary 
Fig. S4). Bacterial richness decreased with supplementation with any bile acid, and diversity reduced when UDCA 
was included in the diet only (Supplementary Fig. S5). Increases in Proteobacteria, in particular, were seen with 
CA supplementation, whilst UDCA diets were associated with increased Bacteroidetes, similar to the changes 
observed in human faeces (Fig. 3a). Caecal bile acid levels reflected the dietary bile acid load, in particular with 
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Figure 1. The faecal microbiota profiles of cholestatic and uncomplicated pregnancy cluster according to 
the ratio of Bacteroidetes to Firmicutes. (a) Distribution of microbes at phylum level in women with normal 
pregnancies (n = 14), women with intrahepatic cholestasis of pregnancy (ICP) treated with ursodeoxycholic 
acid (UDCA, n = 17), and women with untreated ICP (n = 4). (b) Heat map demonstrating unsupervised 
clustering of faecal samples by microbiota profiles determined from 16 S rRNA gene sequencing, according to 
B:F (the ratio of Bacteroidetes to Firmicutes). Each row refers to faecal samples from individual women as per 
(a), uncomplicated pregnancy: blue status; ICP treated with UDCA: purple status; untreated ICP: green status; 
red status shows methodological control. Box colours show relative bacterial abundance, dark blue reflecting 
minimal sequences present in samples – red showing high sequence levels in samples. (c) NMDS analysis of 
16 S rRNA gene sequences from human faecal samples as per (a), demonstrating clustering according to ratio of 
Bacteroidetes to Firmicutes (B:F). Red: high B:F, blue: low B:F, green: parity of B:F. (d) Bile salt hydrolase activity 
of human faecal samples as per (a), according to ratio of Bacteroidetes to Firmicutes (B:F), determined by nmol 
of deoxycholic acid (DCA) production per mg of protein per minute. Tukey box-plots show median, IQR and 
whiskers at 1.5 IQR. Significance determined by one-way ANOVA with Tukey post hoc comparison, ANOVA 
(F(2,32  =  3.55), p = 0.040); *p = 0.038.
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higher secondary bile acids produced by bacterial modification of the supplemented bile acids (DCA from CA, 
LCA from UDCA) (Fig. 3c). Conversely, ω-muricholic acid (ωMCA) is produced by bacterial modification of α- 
and βMCA, which are produced by de novo hepatic synthesis; this was significantly lower for mice from all groups 
supplemented with dietary bile acids. Further, UDCA-supplemented diets resulted in higher unconjugated bile 
acids than control or CA supplementation alone (Fig. 3d).
Similar changes to the caecal findings were seen in the bile acid content of the corresponding murine faeces 
(Fig. 3e). Notable exceptions were that CA supplementation resulted in significantly higher CA levels in the faeces 
of supplemented mice than controls, which was not seen in the caecum; and the highly significant elevations of 
LCA with UDCA treatment found in the caecum were not present in the faeces. In contrast to the caecal results, 
CA supplementation resulted in higher levels of unconjugated bile acid than control or UDCA-fed mice (Fig. 3f).
Discussion
This study has identified that UDCA-treatment in cholestatic pregnancy can alter the composition of gut micro-
biota, increasing the proportion of Bacteroidetes with associated increased BSH activity. This change results in an 
altered intestinal bile acid environment, with more unconjugated bile acids available for enhanced secondary bile 
acid production, and increased FGF19-mediated enterohepatic feedback. Lower C4 concentrations were con-
sistent with increased negative feedback on de novo hepatic bile acid synthesis through fibroblast growth factor 
receptor 4/ beta-klotho hepatic signalling. This finding is consistent with reports of reduced serum concentrations 
of the endogenous primary bile acids in UDCA-treated women15.
Observational studies of human disease are subject to many confounders, which are particularly difficult to 
control for in pregnancy. A limitation of this study is the interindividual variability present for the relatively small 
number of women participating, for whom other clear confounders have been excluded. To address this, we used 
a murine model of cholestatic pregnancy supplemented with oral UDCA, and examined how the caecal intesti-
nal microenvironment was affected by UDCA treatment. At the phylum-level, UDCA-supplementation of mice 
resulted in similar alterations to those seen for women with ICP treated with UDCA, notably a higher proportion 
of Bacteroidetes with a correspondingly lower proportion of Firmicutes. Previous studies have demonstrated that 
dietary cholic acid-associated enrichment of the microbiota with Bacteroidetes was associated with increased bsh 
gene read counts, and these originated from this group of bacteria13. Our findings are consistent with this obser-
vation following UDCA treatment, as this resulted in higher proportions of unconjugated bile acids in the caecum 
compared to control mice, and no corresponding rise in taurine-conjugated bile acids, which would be expected 
if this resulted entirely from the additional dietary load.
Ursodeoxycholic acid may reduce the non-UDCA total serum bile acids for women with ICP8,9,15. This mecha-
nism of action has been attributed to increased hepatic bile acid secretion, with enhanced choleresis secondary to 
vesicular exocytosis (reviewed by Beuers et al.)16. Herein, we provide a complementary explanation: by enhancing 
enterohepatic feedback via FGF19, UDCA can reduce hepatic bile acid synthesis de novo.
FGF19 is produced upon bile acid ligand binding to FXR, although UDCA itself is not a strong FXR ago-
nist in intestinal cells17. UDCA is modified by intestinal bacteria to produce alternative secondary bile acids; 
7β-dehydroxylation results in the formation of LCA, which explains its significantly higher levels in the faeces of 
UDCA-treated women with ICP than other pregnant groups; but LCA also causes induction of intestinal FXR to 
produce FGF1918. UDCA can also be converted by bacterial 7α- and 7β-hydroxysteroid dehydrogenase into the 
potent intestinal FXR agonist CDCA18,19. Although it did not reach statistical significance after adjustment for 
multiple comparisons, an increase in CDCA was observed in the faeces of UDCA-treated women; it is likely that 
levels of CDCA are higher in the terminal ileum than the faeces since it is efficiently uptaken by passive diffusion, 
via ASBT when conjugated, or biotransformed to LCA (reviewed by Crosignani et al.)20. Thus, CDCA agonism 
may explain the increased FGF19 levels seen in UDCA-treated women. Mechanisms to safely obtain terminal 
ileal content samples in pregnant women would be required to support this conclusion.
We confirmed that an increase in the CDCA:CA ratio occurs in the serum of women with ICP during UDCA 
treatment15,21. We conclude that hepatic bile acid synthesis via the classical pathway to produce CA is more 
affected by UDCA treatment than intra- and extra-hepatic synthesis of CDCA via the alternative pathway, sec-
ondary to the hepatic action of FGF19. This is consistent with the effect of FGF19 analogue administration, 
where the bile acid profile in mice reduces CA in favour of MCA synthesis22. In the murine model, treatment 
High B:F (n = 7) 
Median (IQR)
Low or Parity B:F 
(n = 10) Median (IQR) Comparison
Maternal age (years) 36 (34 to 40) 35 (29 to 38) ns
Gestation itch commenced (week+day) 28+3 (21+0 to 29+0) 32+4 (29+0 to 34+4) ns
Gestation of sample (week+day) 35+5 (30+5 to 36+5) 36+5 (34+4 to 37+1) ns
UDCA total dose prior to sample (g)* 76 (15 to 92) 10 (1 to 19) p = 0.004
Peak bile acid concentration pre-sample (µmol/L) 65 (41 to 214) 40 (26 to 75) ns
Bile acid concentration at time of sample (µmol/L) 46 (21 to 136) 29 (19 to 50) ns
Peak bile acid concentration throughout pregnancy (µmol/L) 78 (64 to 254) 60 (29 to 109) ns
Table 1. Clinical features of women treated with UDCA based upon the ratio of Bacteriodetes to Firmicutes. 
B: Bacteroidetes; F: Firmicutes; n: number; IQR: interquartile range; ns: not significant. *Total UDCA dose 
assuming 100% compliance, calculated using prescribed dose(s) and duration. Comparisons using two-tailed 
student’s t-tests, p < 0.05 defined as threshold of significance.
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Figure 2. Women treated with ursodeoxycholic acid for cholestatic pregnancy have altered faecal bile acids and 
enhanced enterohepatic feedback. (a) Faecal bile acids from women in the third trimester of uncomplicated 
pregnancy (blue boxes, n = 14), untreated ICP (green boxes, n = 4), and ICP treated UDCA (purple boxes, 
n = 17). Groups were compared with 2-way ANOVA with Tukey’s multiple comparisons test; ****adjusted 
p < 0.0001, *adjusted p = 0.0294. CA: cholic acid, CDCA: chenodeoxycholic acid, DCA: deoxycholic acid, 
LCA: lithocholic acid, MCA: muricholic acid, HCA: hyocholic acid, HDCA: hyodeoxycholic acid, MDCA: 
murideoxycholic acid, TCA: taurocholic acid, TCDCA: taurochenodeoxycholic acid, TDCA: taurodeoxycholic 
acid, TLCA: taurolithocholic acid, TUDCA: tauroursodeoxycholic acid, TβMCA: taurobetamuricholic 
acid, GCA: glycocholic acid, GCDCA: glycochenodeoxycholic acid, GDCA: glycodeoxycholic acid, GLCA: 
glycolithocholic acid, GUDCA: glycoursodeoxycholic acid. (b) Faecal bile acids by conjugation, from samples 
as per (a). Groups were compared with 2-way ANOVA with Tukey’s multiple comparisons test; ***adjusted 
p = 0.0003, *adjusted p = 0.0277. (c) Faecal bile acid levels according to ratio of Bacteroidetes to Firmicutes 
(B:F), determined by unsupervised clustering, from samples as per (a). Groups compared with Kruskal-
Wallis test with Dunn’s multiple comparisons test; **adjusted p = 0.0086, *adjusted p = 0.0470. (d) Faecal 
bile acid levels by conjugation according to bile salt hydrolase (BSH) activity. Low BSH activity (white boxes): 
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with UDCA alone or in combination with CA did not reduce βMCA. However, UDCA alone did reduce CA, 
demonstrating that its use could alter the balance of classical/alternative bile acid synthesis pathways in the liver, 
similar to humans.
The difference in our findings between enhancement of FGF19 release compared with the reductions seen in 
morbidly obese individuals treated with UDCA23 may reflect the different underlying states of study individuals. 
Distal ileal FXR expression has been correlated with body mass index, with obese individuals having 3-fold higher 
FGF19 mRNA measured24. Notably, ICP is not associated with maternal obesity25. Furthermore, the effects of 
pregnancy and obesity on the composition of the gut microbiota differ considerably: pregnancy is associated with 
an increase in bacterial diversity and higher Bacteroidetes13 whilst a number of studies of obesity report reduced 
diversity with lower Bacteroidetes26–29. Our findings are consistent with those following faecal microbiota trans-
plant for the treatment of Clostridioides difficile, which results in enhanced FGF19 enterohepatic feedback sec-
ondary to restoration of intestinal bacteria, in particular those encoding BSH activity30. Additionally, ileal apical 
sodium-dependent bile acid transporter (ASBT) protein levels fall in pregnancy13, for which conjugated bile acids 
are the preferred substrate for bile acid uptake by the enterocyte. Thus, passive diffusion of unconjugated bile 
acids is likely of greater relevance in pregnancy to affect subtrate availability for intestinal FXR signalling, which is 
dose dependent31; this is consistent with findings that unconjugated bile acids (CDCA and DCA) increase FGF19 
gene expression in two intestinal cell lines (Caco-2 and T84)32.
Additionally, this study suggests a mechanism by which treatment with UDCA might improve GLP1 release 
(and thus impaired glucose tolerance) in ICP. The marked elevation of LCA in the faeces of treated women is 
likely to provide a local agonist to intestinal enteroendocrine L cells, which we confirmed in explants triggers 
GLP1 release, likely by signalling via TGR5. This result is consistent with a recent meta-analysis of seven stud-
ies (626 participants) assessing glycaemic markers in patients treated with UDCA, which found reductions in 
fasting blood glucose, glycosylated haemoglobin and insulin levels compared to control patients, in studies in 
non-alcoholic steatohepatitis, NAFLD and type 2 diabetes mellitus33.
This study supports the conclusion that the secondary modifications of UDCA by bacteria to 
metabolically-active bile acids are important in delivering the intestinally-derived benefits of UDCA treatment 
in ICP. Although unconjugated UDCA is delivered to the intestines from the ingested medication for treated 
women, the efficiency of the enterohepatic circulation and subsequent conjugation in the liver enable subse-
quent biliary secretion of conjugated UDCA. Modification of this to LCA or CDCA requires cleavage from 
the conjugated bile acid by bacterial BSH . Hence, we conclude that an intestinal environment favourable to 
bile salt hydrolase-producing bacteria is likely to enhance enterohepatic feedback. Women with a high ratio of 
Bacteroidetes:Firmicutes were more likely to be taking UDCA (7/8), however others taking UDCA had a low ratio 
(6/14), and correspondingly reduced BSH activity in the faeces. This biological variation may explain the differing 
clinical responses to UDCA that we have observed for women with ICP34, and provide an additional treatment 
target (enriching the intestinal microbiota with BSH-producing bacteria) to provide in combination with UDCA 
for the treatment of ICP. Identification of women with a high Bacteroidetes:Firmicutes signature prior to treatment 
may predict better response to treatment with UDCA, and future studies could use this as a predictive tool to 
treatment response. Alternatively, the observation that women with a high ratio of Bacteroidetes:Firmicutes had 
taken significantly more UDCA prior to sample donation than those women with a lower ratio suggests that there 
is a dose-response to UDCA treatment that may affect the composition of the gut microbiota. The lower quartile 
of UDCA exposure for women with high Bacteroidetes:Firmicutes was more than 2 g/day for one week, providing 
the first evidence for minimal effective dosing for UDCA in ICP.
Methods
Human studies. The study was approved by the ethics committee of Hammersmith Hospitals NHS Trust, 
London (08/H0707/21 and 11/LO/0396), and performed according to the principles of the 1975 Declaration of 
Helsinki. Written informed consent was obtained from all participants prior to inclusion in the study. Women 
were opportunistically recruited in the third trimester of pregnancy to donate faecal samples; these were obtained 
from 21 women with ICP and 14 women with uncomplicated pregnancies. ICP was confirmed by demonstration 
of serum bile acids > 10 µmol/L in association with pruritus, with no additional identifiable cause for their liver 
dysfunction. Women were restricted to those with spontaneously conceived third trimester singleton pregnan-
cies, who had not taken antibiotics for the duration of the pregnancy, and did not report any other pregnancy 
complications. Faecal samples were frozen at −80 °C within 24 hours of sample collection, and sections from the 
same sample used for metataxonomics, bile acid measurement and BSH activity assays.
Serum samples were obtained from women following a standardised diet from 18:00 the preceding day. 
Serum FGF19 and C4 levels were analysed as previously described13 from serum samples obtained at 15:00 
0.00–0.83 nmol DCA/mg/min (n = 24), high BSH activity (grey boxes): 2.23–5.31 nmol DCA/mg/min (n = 11). 
Groups compared with Mann-Whitney tests, *p = 0.0106. (e) Serum fibroblast growth factor 19 (FGF19) and 
7α-hydroxy-4-cholesten-3-one (C4) concentrations from women in the third trimester of uncomplicated 
pregnancy (blue boxes, n = 24), untreated ICP (green boxes, n = 10) and UDCA-treated ICP (purple boxes, 
n = 10). Samples were taken at 15:00, following a standardized diet for 21 hours. Groups compared with 
multiple t tests, and Holm-Sidak correction for multiple testing. For FGF19: *p = 0.0302, for C4: normal vs ICP 
on UDCA *p = 0.0296, ICP untreated vs ICP on UDCA *p = 0.0335. (f) Percentage of glucagon-like peptide 
one (GLP1) released from murine colonic tissue on exposure to the bile acids LCA and DCA. Negative control – 
buffer only, positive control: 10 µM 3-isobutyl-1-methylxanthine (IBMX) with 10 µM forskolin (n = 4, with 7–8 
replicates per experiment). Boxes show median and interquartile range (IQR), with whiskers at 1.5 IQR.
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Figure 3. Ursodeoxycholic acid dietary supplementation for pregnant mice increases caecal Bacteroidetes and 
unconjugated bile acids. (a) Distribution of microbes at phylum level in day 18 pregnant mice given a normal 
chow (control) diet (n = 7), 0.5% cholic acid (CA) supplemented diet (n = 7), 0.5% ursodeoxycholic acid (UDCA) 
supplemented diet (n = 6) and 0.5% CA + 0.5% UDCA supplemented diet (n = 7). (b) NMDS plot demonstrating 
distribution of gut microbiota according to diet, for mice as per (a). (c) Caecal bile acids from pregnant mice as 
per (a). Control: blue boxes, 0.5% CA diet: green boxes, 0.5% UDCA diet: purple boxes, 0.5% CA + 0.5% UDCA 
diet: pink boxes. DCA: deoxycholic acid, LCA: lithocholic acid, MCA: muricholic acid, HDCA: hyodeoxycholic 
acid, MDCA: murideoxycholic acid, TCA: taurocholic acid, TUDCA: tauroursodeoxycholic acid, TβMCA: tauro-
betamuricholic acid, TωMCA: tauro-omegamuricholic acid, TαMCA: tauro-alphamuricholic acid. (d) Caecal bile 
acids by conjugation, from pregnant mice as per (a). Control: blue boxes, 0.5% CA diet: green boxes, 0.5% UDCA 
diet: purple boxes, 0.5% CA + 0.5% UDCA diet: pink boxes. (e) Faecal bile acids from pregnant mice as per (a). 
Control: blue boxes, 0.5% CA diet: green boxes, 0.5% UDCA diet: purple boxes, 0.5% CA + 0.5% UDCA diet: pink 
boxes. (f) Faecal bile acids by conjugation, from pregnant mice as per (a). Control: blue boxes, 0.5% CA diet: green 
boxes, 0.5% UDCA diet: purple boxes, 0.5% CA + 0.5% UDCA diet: pink boxes. Groups were compared with 
2-way ANOVA with Tukey’s multiple comparisons test; adjusted p values where p < 0.05: a control vs CA; b control 
vs UDCA; c control vs CA+UDCA, d CA vs UDCA; e CA vs CA+UDCA; f UDCA vs CA+UDCA. Boxes show 
median and interquartile range (IQR), with whiskers at 1.5 IQR.
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(correspondent with peak FGF19) for 24 women with uncomplicated pregnancies, and 20 women with ICP (10 
untreated, and 10 treated with UDCA). The measurement of individual serum bile acids was previously described 
in a study of the effect of UDCA treatment on serum bile acid profile15; we used these data to calculate the ratio 
of CA:CDCA for new comparison.
Murine studies. The experiments were conducted according to the UK Animals (Scientific Procedures) Act 
of 1986, with approval of the King’s College London Animal Studies Committee. Age-matched female C57BL/6 
mice (Harlan Laboratories, Bicester, UK) were housed in the same room, with a 12-hour light cycle, with 3 mice 
per cage according to dietary group. Mice were fed, ad libitum a normal chow (RM3, Special Diets Services, Essex, 
UK) control diet, or an RM3 diet supplemented with 0.5% CA, 0.5% UDCA, or 0.5% CA plus 0.5% UDCA (LBS 
Biotechnology, Horley, UK, n = 6–7 per group), and after one week were mated. Mice were sacrificed at day 18 of 
pregnancy, at which time caeca and faeces were harvested, snap frozen on dry ice and stored at −80 °C.
Primary colonic culture secretion studies were performed as previously described35. In brief, male C57BL/6 
mice fed a control diet were sacrificed at 10–12 weeks of age, and colons were harvested. 1mm2 squares of 
cleaned colon were digested with collagenase from Clostridium histolyticum (Sigma-Aldrich, St Louis, US) in 
Dulbecco’s-modified Eagle medium (DMEM) (Sigma-Aldrich, St Louis, US), and cultured overnight on 1% 
Matrigel-coated plates (Corning, New York, US) and DMEM with 10% fetal calf serum and 1% penicillin and 
streptomycin(Sigma-Aldrich, St Louis, US). Cultures were treated with 100 µM LCA or 100 µM DCA, and 10 µM 
3-isobutyl-1-methylxanthine (IBMX)/forskolin used as a positive control, for 2 hours. GLP1 concentrations were 
measured by ELISA (Millipore Sigma, Burlington, US) for the supernatant and lysed cells, and GLP1 release cal-
culated as a percentage of total levels.
Metataxonomic sequencing. Murine caecal content was separated from overlying intestine whilst frozen 
with macroscopic dissection. Human faecal aliquots (200 mg) and murine caecal content were lysed using the 
Qiagen Tissuelyser II bead beater (25 Hz for 20 minutes), with DNA extracted using the QiaAMP Fast DNA Stool 
Mini Kit (Qiagen, Venlo, Netherlands), according to manufacturer’s instructions.
16S rRNA gene sequencing was performed with the Illumina MiSeq platform (Illumina Inc., Saffron Waldon, 
UK). Human faecal 16S rRNA gene sequencing using V1-V3 primers was performed by Research and Testing 
Laboratories, Texas, as per published protocols36, whilst murine caecal 16S rRNA gene sequencing was per-
formed using V1-V2 primers in house37. Murine caecal sample libraries were cleaned and normalised using 
the SequalPrep Normalization Plate Kit (Life Technologies, Paisley, UK). Sample library quantification was 
performed with the NEBNext Library Quant Kit for Illumina (New England Biolabs, Hitchin, UK), and 300 bp 
paired-end sequencing performed using the MiSeq Reagent Kit v3 (Illumina). Data were analysed using Mothur 
software38, with nucleic acid sequences aligned using the SILVA database39 and classified using the ribosomal data 
project (RDP) database reference sequence files according to Wang et al.40. Statistical analyses were performed in 
R, using the Vegan package to perform non-metric multidimensional scaling (NMDS) and permutational multi-
variate analysis of variation (PERMANOVA). The Statistical Analysis of Metagenomic Profiles (STAMP) software 
was used to compare groups at taxonomic levels, using the Kruskal-Wallis H-test with Tukey-Kramer post hoc 
testing and correction for multiple testing with Benjamini-Hochberg FDR. Alpha diversity (Shannon diversity 
index) and richness (total number of bacterial taxa observed) calculated in Mothur were compared using SPSS 
version 23 (IBM, New York, USA).
Bile salt hydrolase activity assay. Faecal water was prepared and total faecal protein quantified similarly 
to a method previously-described41, but with the addition of bacterial and mammalian protease inhibitor cock-
tails (G Biosciences, Uttar Pradesh, India), as well as Dithiothreitol to 1 mM final concentration (Roche, Basel, 
Switzerland) (to minimise enzyme oxidation42).
The BSH assay has been described previously37. In brief, BSH activity was determined by measuring insoluble 
DCA precipitated (determined by absorbance at 600 nm (A600)) following incubation of 500 µg of faecal protein 
with taurodeoxycholic acid (Sigma-Aldrich, St Louis, US). Samples were compared with a standard curve of 
known DCA concentrations and measured in triplicate.
Bile acid quantification. Faecal and caecal samples were homogenized in methanol (containing internal 
standards) with ceramic beads using the Qiagen Tissuelyser II as previously described43. Following centrifuga-
tion, 20 µL supernatant was diluted with 980 µL MeOH:H2O 1:1. Bile acids were separated and detected using 
ultra-performance liquid chromatography coupled to mass spectrometry, as previously reported43. Quantification 
was made using an external standard curve.
Statistical analyses. Where not otherwise indicated in the methods, results were compared using GraphPad 
Prism (version 7.02) using Fisher’s exact test, analysis of variation (ANOVA) and Tukey’s multiple comparisons 
test (accounting for multiple measures), Kruskal-Walllis test with Dunn’s multiple comparisons test (accounting 
for multiple measures), multiple t test with Holm-Sidak correction for multiple comparisons or Mann-Whitney 
tests, dependent upon normality of data.
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
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